Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Elevance Health Inc’s stock clocked out at $322.33, up 1.15% from its previous closing price of $318.65. In other words, the price has increased by $1.15 from its previous closing price. On the day, 1.95 million shares were traded. ELV stock price reached its highest trading level at $325.655 during the session, while it also had its lowest trading level at $317.75.
Ratios:
To gain a deeper understanding of ELV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310. Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 72581619712 and an Enterprise Value of 68104724480. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.72, and their Forward P/E ratio for the next fiscal year is 10.13. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 0.36 whereas that against EBITDA is 7.179.
Stock Price History:
The Beta on a monthly basis for ELV is 0.60, which has changed by -0.41106504 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is 1.55%, while the 200-Day Moving Average is calculated to be -15.03%.
Shares Statistics:
It appears that ELV traded 2.37M shares on average per day over the past three months and 2013870 shares per day over the past ten days. A total of 224.84M shares are outstanding, with a floating share count of 224.71M. Insiders hold about 0.21% of the company’s shares, while institutions hold 92.73% stake in the company. Shares short for ELV as of 1755216000 were 3156964 with a Short Ratio of 1.33, compared to 1752537600 on 2719541. Therefore, it implies a Short% of Shares Outstanding of 3156964 and a Short% of Float of 1.39999995.
Dividends & Splits
With its trailing 12-month dividend rate of 6.68, ELV has a forward annual dividend rate of 6.68. Against a Trailing Annual Dividend Yield of 0.02096344The stock’s 5-year Average Dividend Yield is 1.23. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-06-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
Elevance Health Inc (ELV) is presently subject to a detailed evaluation by 16.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $4.11, with high estimates of $4.54 and low estimates of $1.96.
Analysts are recommending an EPS of between $32.15 and $28.77 for the fiscal current year, implying an average EPS of $30.02. EPS for the following year is $32.71, with 21.0 analysts recommending between $39.23 and $26.97.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $49.22B. It ranges from a high estimate of $50.2B to a low estimate of $48.65B. As of the current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.36B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $47.78B.
A total of 12 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $194.96B, resulting in an average revenue estimate of $196.92B. In the same quarter a year ago, actual revenue was $175.2BBased on 10 analysts’ estimates, the company’s revenue will be $208.37B in the next fiscal year. The high estimate is $213.85B and the low estimate is $200.55B.
